Obesity treatment is shifting toward long-term disease management—where the goal is not only to reduce weight but also to maintain it safely and sustainably. New agents targeting gut–brain and metabolic pathways have expanded available treatment options, while also underscoring the need to address long-term engagement.

Adherence remains a key challenge. Real-world evidence shows that many patients discontinue therapy within the first year, often due to side effects, administration burden, or mismatched expectations. As new formats emerge—including oral formulations—treatment strategies are evolving to better align with patient preferences and routines.

Studies suggest that mode and frequency of administration can influence persistence. Some patients prefer the simplicity of once-weekly injections; others find daily oral dosing easier to incorporate. These differences highlight the need for early, personalized conversations about lifestyle fit, tolerability, and long-term commitment.

Pharmacotherapy is just one pillar of sustainable obesity care. Lasting outcomes still rely on nutrition, behavioral support, and structured follow-up. The opportunity now lies in integrating these therapies into adaptable models that reinforce patient engagement well beyond the initial response.

How do you navigate adherence challenges when patients transition between therapy formats? What potential do emerging oral options hold for improving persistence in long-term obesity care?